Answers are grounded in this paper and cite their sources.
Isoniazid (INH) is a first-line anti-tuberculosis drug; however, its dose-dependent hepatotoxicity limits clinical use. Conventional in vitro models lack the sequential gut absorption–liver metabolism interface, and animal models exhibit poor human translation. Here, we developed a gut-liver-on-chip model to simultaneously assess INH absorption and subsequent hepatotoxicity. A dual-organ chip was constructed with an intestinal barrier (Caco-2/HT29-MTX-E12, 9:1 ratio) and liver spheroids composed of HepG2, HUVEC-T1, phorbol myristate acetate-induced THP-1, and human hepatic stellate cells. INH was added to the intestinal chamber at concentrations of 10.6 mM and 15.8 mM. Drug concentrations in the liver chamber were quantified by high-performance liquid chromatography at 0, 2, 4, 8, 24, 32, and 48 h. After 48 h, intestinal barrier integrity was assessed by transepithelial electrical resistance (TEER), and hepatotoxicity was evaluated by measuring aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB), and propidium iodide (PI) staining of dead cells. INH was detected in the liver chamber within 2 h and reached equilibrium at 48 h in a dose-dependent manner. Both INH concentrations significantly increased AST and ALT levels, reduced ALB secretion, and increased PI-positive dead cells in liver spheroids compared with the control group (P < 0.05). TEER values decreased dose-dependently, indicating moderate intestinal barrier damage. In conclusion, this gut-liver-on-chip model enables dynamic monitoring of intestinal-to-liver drug transfer combined with endpoint assessment of organ-level toxicity, providing a human-cell-based proof-of-concept platform for preclinical safety evaluation of orally administered drugs with hepatotoxic potential.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: